ArticleNeuro-oncology advances
New-onset facial spasm is associated with treatment failure after radiosurgery in vestibular schwannoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New-onset facial spasm (NOFS) has been reported to be a post-therapeutic side effect, when treating vestibular schwannoma (VS) with radiosurgery (SRS) and has been linked to post-treatment pseudoprogression. The aim of this study was to identify risk factors for developing NOFS after SRS treatment and to investigate NOFS as a clinical parameter for radiographic tumor response in VS. Methods: This study included all consecutive patients of Results: The incidence of NOFS was 5% overall. In total, 62% were permanent NOFS, whereas 39% recovered spontaneously between 4 and 34 months, postinterventionally. The incidence of NOFS was unrelated to tumor volume-however, previous SRS increased the incidence of NOFS to 20%. In primary SRS therapy, facial spasm was associated with a higher recurrence rate compared to non-NOFS patients in the Kaplan-Meier analysis ( Conclusions: The risk of NOFS was significantly higher in recurrent compared to primary treatment (20% vs 5%) and the majority of NOFS was permanent. The incidence of permanent NOFS was significantly associated with treatment failure. Temporary NOFS was associated with pseudoprogression. Future analysis comparing the risk profile of either treatment option should include facial spasm as a significant VS-related postinterventional symptom. Patients with postinterventional NOFS should be followed-up long-term for higher risk of treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.